Human Rhinovirus (HRV) is reported to be a leading cause of up to 80% of asthma exacerbations. The viral pathway and associated immune responses represent a potential key therapeutic target for new and novel asthma treatments. The use of a human viral challenge model has been widely explored over the last few decades and there is interest in its use to enhance early clinical development.
Sign up to our emails and follow us on social media to keep up to date with hVIVO.
